2025-06-04-Jefferies-Establishment_Labs（ESTA）_帝国心态_美国市场向好；非美国市场稳定；重申盈利目标_8页_107kb

Company Overview and Key Business Highlights

Establishment Labs (ESTA) is a medical technology firm specializing in silicone gel-filled breast implants, with a global presence in 80 countries and headquarters in Costa Rica.

Financial Performance and Guidance

• US and domestic markets show strong momentum, with sales exceeding expectations and projected to meaningfully exceed $35MM for the year. OUS markets are stable, with growth in APAC and EMEA.
• ESTA targets EBITDA positivity in 2H25 and cash-flow break-even in 2026, driven by US sales mix and higher-priced implants.
• Key pipeline products include MIA (FY25 sales $8-10MM), Preserve, and Recon.

Valuation and Investment Recommendation

• Jefferies maintains a BUY rating with a price target of $61.00 (+66% upside from current price). Valuation based on ~6-7x 2026 sales, compared to previous ratings.
• Market cap is $1.0B, with analysts monitoring risks like competition, macro conditions, and distributor reliance.

Risks

• Competition may lead to discounting; overall market conditions could affect aesthetic procedures.
• Challenges in LatAm (e.g., Brazil) and uncertainties in the China ramp-up phase.

Analyst Certification and Key Notes

• Analysts certify views reflect personal views, with compensation linked to performance.
• Emphasis on strong account growth and order rates in the US, a key growth driver.